2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T720,The persistence of immunological memory after immunization against monkeypox virus (MPXV) is unclear. This study assessed MPXV-specific neutralizing antibodies (NAbs) at >2 years from Mpox or Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) vaccination. Retrospective study including individuals with previous Mpox or vaccination with MVA-BN, whose MPXV-specific NAb titers were already assessed at six months from either event at our center. Neutralizing titers were determined at >2 years from Mpox or vaccination by Plaque Reduction Neutralization Test (PRNT) [positive≥1:10] as the maximum dilution with reduction of cytopathic effect of 90% and 50% (IC90-IC50). Groups were compared using chi-square test, Fisher's exact test or Wilcoxon rank-sum test. Association between titers at >2 years and individuals characteristics was evaluated with ordinal logistic regression. Overall, 48 individuals with previous Mpox and 42 vaccinees were included, all were men. At >2 years from Mpox or vaccination, 22/90 (24.44%) and 53/90 (58.8%) had positive NAb titers respectively at IC90 and IC50. At IC50 previous Mpox was associated with positive titers (68.75% vs 47.62%; p=0.042), with univariate analysis associating higher titers at six months to higher titers at >2 years (OR=6.45,95%CI=1.89-22.07;p=0.003). At multivariate analysis, historical smallpox vaccination was associated to higher titers at >2 years (OR=5.37,95%CI=1.31-22.00;p=0.020), whilst previous Mpox was marginally associated (OR=2.08,95%CI=0.94-4.62;p=0.073). MPXV-specific NAbs waned at >2 years from previous infection or vaccination, often becoming undetectable. Higher NAb titers at six months (univariate) and prior smallpox vaccination (multivariate) were associated with NAb detection at >2 years, whilst previous Mpox was marginally associated.31:T9d9,Abstract Background The persistence of immunological memory after immunization against monkeypox virus (MPXV) is unclear. This study assessed MPXV-specific neutralizing antibodies (NAbs) at >2 years from Mpox or Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) vaccination. Methods Retrospective study including individuals with previous Mpox or vaccination with MVA-BN, whose MPXV-specific NAb titers were already assessed at six months from either event at our center. Neutralizing titers were determined at >2 years from Mpox or vaccination by Plaque Reduction Neutralization Test (PRNT) [positive≥1:10] as the maximum dilution with reduction of cytopathic effect of 90% and 50% (IC90-IC50). Groups were compared using chi-square test, Fisher’s exact test or Wilcoxon rank-sum test. Association between titers at >2 years and individuals characteristics was evaluated with ordinal logistic regression. Results Overall, 48 individuals with previous Mpox and 42 vaccinees were included, all were men. At >2 years from Mpox or vaccination, 22/90 (24.44%) and 53/90 (58.8%) had positive NAb titers respectively at IC90 and IC50. At IC50 previous Mpox was associated with positive titers (68.75% vs 47.62%; p=0.042), with univariate analysis associating higher titers at six months to higher titers at >2 years (OR=6.45,95%CI=1.89–22.07;p=0.003). At multivariate analysis, historical smallpox vaccination was associated to higher titers at >2 years (OR=5.37,95%CI=1.31-22.00;p=0.020), whilst previous Mpox was marginally associated (OR=2.08,95%CI=0.94-4.62;p=0.073). Conclusions MPXV-specific NAbs waned at >2 years from previous infection or vaccination, often becoming undetectable. Higher NAb titers at six months (univariate) and prior smallpox vaccination (multivariate) were associated with NAb detection at >2 years, whilst previous Mpox was marginally associated. 32:T711,On 14 August 2024, the WHO redesignated Monkeypox (mpox) as a Public Health Emergency of International Concern. Ocular disease is under-recognised and can cause irreversible vision loss. Clarifying its burden, clade-specific patterns and HIV-related risks is essential for clinical care and public health. We conducted an umbrella review and meta-analysis, systematically searching PubMed, Embase, Scopus, Web of Science and the Cochrane Library from inception to September 2025. Eligible studies were systematic reviews reporting ophthalmic manifestations in laboratory-confirmed mpox cases, stratified by viral clades I, II and IIb. Pooled proportions were estimated using random-effects meta-analysis, with clade-stratified subgroup analyses. The protocol was registered in PROSPERO (CRD420251137180). Five systematic reviews (36 primary studies; 28 139 patients) were included. The pooled proportion of conjunctivitis was 8.9% (95% CI 4.8 to 13.9), highest in clade I (21.9%) and lowest in clade IIb (2.7%). Keratitis (1.5%), eyelid lesions (3.3%), conjunctival lesions (8.4%) and corneal ulceration (3.3%) varied by clade. Visual impairment occurred in 4.5% overall; unilateral (0.9%) and bilateral (0.4%) blindness were reported only with clade I. Across reviews, people living with advanced HIV experienced disproportionately higher rates of severe and persistent ocular complications than HIV-negative individuals. Mpox-related ophthalmic disease can cause substantial-and potentially preventable-visual disability. Clade I infection is associated with a greater burden of ocular complications than clade II-particularly IIb. Improved access to eye health services, early recognition and integration of HIV and mpox care are critical to reducing vision loss, especially in resource-limited settings.33:T960, Background On 14 August 2024, the WHO redesignated Monkeypox (mpox) as a Public Health Emergency of International Concern. Ocular disease is under-recognised and can cause irreversible vision loss. Clarifying its burden, clade-specific patterns and HIV-related risks is essential for clinical care and public health. Methods We conducted an umbrella review and meta-analysis, systematically searching PubMed, Embase, Scopus, Web of Science and the Cochrane Library from inception to September 2025. Eligible studies were systematic reviews reporting ophthalmic manifestations in laboratory-confirmed mpox cases, stratified by viral clades I, II and IIb. Pooled proportions were estimated using random-effects meta-analysis, with clade-stratified subgroup analyses. The protocol was registered in PROSPERO (CRD420251137180). Results Five systematic reviews (36 primary studies; 28 139 patients) were included. The pooled proportion of conjunctivitis was 8.9% (95% CI 4.8 to 13.9), highest in clade I (21.9%) and lowest in clade IIb (2.7%). Keratitis (1.5%), eyelid lesions (3.3%), conjunctival lesions (8.4%) and corneal ulceration (3.3%) varied by clade. Visual impairment occurred in 4.5% overall; unilateral (0.9%) and bilateral (0.4%) blindness were reported only with clade I. Across reviews, people living with advanced HIV experienced disproportionately higher rates of severe and persistent ocular complications than HIV-negative individuals. Conclusions Mpox-related ophthalmic disease can cause substantial—and potentially preventable—visual disability. Clade I infection is associated with a greater burden of ocular complications than clade II—particularly IIb. Improved access to eye health services, early recognition and integration of HIV and mpox care are critical to reducing vision loss, especially in resource-limited settings. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Mpox: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Mpox (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Mpox\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Mpox\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Mpox\"}]}}"}}]],["$","$L2f",null,{"title":"Mpox: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Mpox with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1071/sh25250","pmid":"42219251","title":"Self-reported vaccine uptake across six infectious diseases among gay, bisexual, transgender, and non-binary individuals in Australia: findings from a 2024 national survey","journal_title":"Sexual Health","journal_issn":"1448-5028","published_at":"2026-06-01T00:00:00.000Z","url":"https://doi.org/10.1071/sh25250","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-08T13:46:37.924Z","updated_at":"2026-06-08T13:46:37.924Z","tags":[{"paper_doi":"10.1071/sh25250","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"COVID-19","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Hepatitis A","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Hepatitis B","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Human Papillomavirus Infection","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Influenza","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Meningococcal Disease","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Mpox","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"condition","value":"Vaccine-Preventable Diseases","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"COVID-19 vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"hepatitis A vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"hepatitis B vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"HPV vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"influenza vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"meningococcal vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"generic","value":"mpox vaccine","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"modality","value":"Vaccination","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"sample_size","value":"n=2095","value_numeric":2095},{"paper_doi":"10.1071/sh25250","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"warning","value":"Hepatitis A and B uptake were reported as a combined figure (80.6%), so individual vaccine rates cannot be distinguished.","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"warning","value":"The abstract does not describe the recruitment method (e.g., online panel, community outreach), making it difficult to assess selection bias fully.","value_numeric":null},{"paper_doi":"10.1071/sh25250","tag_type":"warning","value":"Trans and gender diverse participants comprised only ~5.3% of the sample; subgroup findings for this population should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"Self-reported uptake of six vaccines (COVID-19, influenza, hepatitis A/B, HPV, meningococcal disease, mpox) among 2,095 GBMSM and trans/gender diverse people in Australia, surveyed July–November 2024, stratified by age, HIV status, PrEP use, gender, education, Medicare status, region of birth, and jurisdiction.","key_result":"COVID-19 had the highest uptake (97.5%), followed by hepatitis A/B (80.6%), influenza (72.8%), mpox (64.0%), HPV (35.9%), and meningococcal disease (30.3%). HIV-negative individuals not on PrEP had consistently lower uptake; higher education and holding a Medicare card were linked to greater uptake across vaccines.","limitations":"Self-reported vaccination status is subject to recall bias and may overestimate true uptake. The sample was 94.7% cisgender men, limiting generalisability to trans and gender diverse people. Recruitment method not detailed in the abstract, raising possible self-selection bias.","practice_takeaway":"Clinicians seeing GBMSM not on PrEP or without a Medicare card should proactively screen and offer HPV and meningococcal vaccines, which had the lowest uptake. Integrating vaccination into routine sexual health care visits may help close these gaps."}},{"doi":"10.1016/s1473-3099(26)00141-6","pmid":"42184813","title":"Performance of five mpox antigen-based rapid diagnostic tests tested on lesion swabs from patients with suspected mpox from the Kinshasa province of DR Congo: a diagnostic accuracy study","journal_title":"The Lancet Infectious Diseases","journal_issn":"1473-3099","published_at":"2026-05-25T00:00:00.000Z","url":"https://doi.org/10.1016/s1473-3099(26)00141-6","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-29T13:23:13.650Z","updated_at":"2026-05-29T13:23:13.650Z","tags":[{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"Beijing Hotgen Biotech Mpox RDT","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"Contipharma Mpox RDT","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"Guangdong Wesail Biotech Mpox RDT","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"Hangzhou Testsea Biotechnology Mpox RDT","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"NG Biotech Mpox RDT","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"brand","value":"RADI FAST Mpox PCR","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"condition","value":"Mpox","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"modality","value":"Antigen-Based Rapid Diagnostic Test","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"sample_size","value":"n=190","value_numeric":190},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"study_design","value":"Diagnostic Accuracy Study","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"warning","value":"All five RDTs were tested against MPXV clade Ib; performance against clade Ia was only assessed analytically (in vitro), not clinically.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the potential shift toward RDT-based screening in resource-limited settings, though uptake will depend on regulatory approval and supply chain factors not addressed in this study.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00141-6","tag_type":"warning","value":"The study was retrospective and supplemented with PCR-negative swabs from external studies, which may affect prevalence estimates and predictive values. Clinicians should interpret PPV/NPV figures in the context of local prevalence.","value_numeric":null}],"summaries":{"what_studied":"Diagnostic accuracy of five mpox antigen-based rapid diagnostic tests (RDTs) was evaluated on lesion swabs from 190 patients with suspected mpox in nine health zones of Kinshasa province, DR Congo (Feb 12 – Jun 28, 2025), using a PCR assay (RADI FAST Mpox) as the reference standard.","key_result":"The best-performing RDT (Guangdong Wesail Biotech) achieved sensitivity of 77.3% (95% CI 68.0–84.5) and specificity of 93.5% (86.6–97.0); the lowest-performing (NG Biotech) had sensitivity of only 39.2% (30.1–49.1) with similarly high specificity (96.8%). All five tests showed high specificity (≥93.5%) but variable sensitivity (39–77%).","limitations":"- Retrospective design using stored swabs may not fully reflect real-world point-of-care conditions.\n- PCR-negative swabs supplemented from other studies, which could introduce selection bias.\n- Study was confined to one province (Kinshasa), limiting generalizability to other regions or clade Ia settings.","practice_takeaway":"In high-prevalence settings like DR Congo, a positive mpox RDT result can support diagnosis when PCR is unavailable — but a negative result does **not** rule out infection given sensitivities as low as 39%. Clinicians should treat RDTs as rule-in, not rule-out, tools for mpox."}},{"doi":"10.1093/infdis/jiag009","pmid":"41492703","title":"A humoral dilemma: reassessing monkeypox virus neutralizing antibodies at more than two years from Mpox or MVA-BN vaccination","journal_title":"The Journal of Infectious Diseases","journal_issn":"0022-1899","published_at":"2026-01-06T00:00:00.000Z","url":"https://doi.org/10.1093/infdis/jiag009","source_score":18,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-11","doi":"10.1093/infdis/jiag009","days":"7","issn":"0022-1899","rank":"7","field":"Clinical Medicine","score":"18","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1093/infdis/jiag009","title":"A humoral dilemma: reassessing monkeypox virus neutralizing antibodies at more than two years from Mpox or MVA-BN vaccination.","journal":"The Journal of infectious diseases","methods":"","results":"Overall, 48 individuals with previous Mpox and 42 vaccinees were included, all were men. At >2 years from Mpox or vaccination, 22/90 (24.44%) and 53/90 (58.8%) had positive NAb titers respectively at IC90 and IC50. At IC50 previous Mpox was associated with positive titers (68.75% vs 47.62%; p=0.042), with univariate analysis associating higher titers at six months to higher titers at >2 years (OR=6.45,95%CI=1.89-22.07;p=0.003). At multivariate analysis, historical smallpox vaccination was associated to higher titers at >2 years (OR=5.37,95%CI=1.31-22.00;p=0.020), whilst previous Mpox was marginally associated (OR=2.08,95%CI=0.94-4.62;p=0.073).","abstract":"$30","keywords":["Humoral immunity","MPXV","MVA-BN","Mpox","Neutralizing antibodies","Vaccine"],"pubmed_id":"41492703","conclusions":"","publication_date":"2026-01-06T00:00:00"},"crossref":{"DOI":"10.1093/infdis/jiag009","URL":"https://doi.org/10.1093/infdis/jiag009","ISSN":["0022-1899","1537-6613"],"link":[{"URL":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiag009/66271858/jiag009.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiag009/66271858/jiag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["A humoral dilemma: reassessing monkeypox virus neutralizing antibodies at more than two years from Mpox or MVA-BN vaccination"],"author":[{"given":"Nicolò","family":"Moschetta","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan, 20132 ,"}]},{"given":"Elena","family":"Criscuolo","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University , 20132, Milan ,"}]},{"given":"Angelo Roberto","family":"Raccagni","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan, 20132 ,"}]},{"given":"Nicolò","family":"Capra","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute , Milan, 20127 ,"}]},{"given":"Riccardo","family":"Lolatto","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute , Milan, 20127 ,"}]},{"given":"Gabriele","family":"Loi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan, 20132 ,"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute , Milan, 20127 ,"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan, 20132 ,"},{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute , Milan, 20127 ,"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan, 20132 ,"},{"name":"Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute , Milan, 20127 ,"}]},{"given":"Nicola","family":"Clementi","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University , 20132, Milan ,"},{"name":"Laboratory of Microbiology and Virology, IRCCS San Raffaele Scientific Institute , Milan, 20132 "}]}],"issued":{"date-parts":[[2026,1,6]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2026-01-03T12:23:41Z","timestamp":1767443021000,"date-parts":[[2026,1,3]]},"indexed":{"date-time":"2026-01-06T09:47:29Z","timestamp":1767692849247,"date-parts":[[2026,1,6]]},"license":[{"URL":"https://academic.oup.com/pages/standard-publication-reuse-rights","start":{"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000,"date-parts":[[2026,1,6]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiag009/8415122"}},"subtitle":[],"deposited":{"date-time":"2026-01-06T09:46:05Z","timestamp":1767692765000,"date-parts":[[2026,1,6]]},"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"published":{"date-parts":[[2026,1,6]]},"publisher":"Oxford University Press (OUP)","reference":null,"short-title":[],"article-number":"jiag009","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["The Journal of Infectious Diseases"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,6]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/infdis/jiag009","is_oa":false,"title":"A humoral dilemma: reassessing monkeypox virus neutralizing antibodies at more than two years from Mpox or MVA-BN vaccination","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-03","best_oa_location":null}},"created_at":"2026-01-16T11:56:46.634Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1093/infdis/jiag009","tag_type":"brand","value":"MVA-BN","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"condition","value":"Mpox","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"modality","value":"Vaccine","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"sample_size","value":"n=90","value_numeric":90},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"warning","value":"All participants were men, which may limit generalizability.","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"warning","value":"Design classification is inferred from the description of a retrospective single‑center cohort.","value_numeric":null},{"paper_doi":"10.1093/infdis/jiag009","tag_type":"warning","value":"Results reflect antibody titers by PRNT (IC50/IC90); no clinical protection outcomes were reported.","value_numeric":null}],"summaries":{"what_studied":"Retrospective study reassessing monkeypox virus neutralizing antibody persistence >2 years after mpox infection (n=48) or MVA‑BN vaccination (n=42) in men with prior 6‑month titers, using PRNT IC90/IC50 positivity (≥1:10).","key_result":"At >2 years, 22/90 (24.44%) were PRNT IC90‑positive and 53/90 (58.8%) IC50‑positive. IC50 positivity was higher after prior mpox vs vaccination alone (68.75% vs 47.62%; p=0.042); higher 6‑month titers predicted higher >2‑year titers (OR 6.45, 95% CI 1.89–22.07; p=0.003), and historical smallpox vaccination independently associated with higher titers (OR 5.37, 95% CI 1.31–22.00; p=0.020), while prior mpox was marginal (OR 2.08, 95% CI 0.94–4.62; p=0.073).","limitations":"Retrospective, single‑center cohort of 90 participants, all male; outcomes were limited to PRNT titers without clinical endpoints.","practice_takeaway":"By >2 years after mpox or MVA‑BN vaccination, neutralizing antibodies often wane and may be undetectable; about 59% remained IC50‑positive and 24% IC90‑positive. Prior smallpox vaccination and higher 6‑month titers marked those more likely to retain antibodies."}},{"doi":"10.1136/bjo-2025-328294","pmid":"41469169","title":"Clade-specific ophthalmic manifestations of mpox: an umbrella review and meta-analysis of systematic reviews","journal_title":"British Journal of Ophthalmology","journal_issn":"0007-1161","published_at":"2025-12-31T00:00:00.000Z","url":"https://doi.org/10.1136/bjo-2025-328294","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1136/bjo-2025-328294","days":"14","issn":"0007-1161","rank":"6","field":"Clinical Medicine","score":"10","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1136/bjo-2025-328294","title":"Clade-specific ophthalmic manifestations of mpox: an umbrella review and meta-analysis of systematic reviews.","journal":"The British journal of ophthalmology","methods":"","results":"Five systematic reviews (36 primary studies; 28 139 patients) were included. The pooled proportion of conjunctivitis was 8.9% (95% CI 4.8 to 13.9), highest in clade I (21.9%) and lowest in clade IIb (2.7%). Keratitis (1.5%), eyelid lesions (3.3%), conjunctival lesions (8.4%) and corneal ulceration (3.3%) varied by clade. Visual impairment occurred in 4.5% overall; unilateral (0.9%) and bilateral (0.4%) blindness were reported only with clade I. Across reviews, people living with advanced HIV experienced disproportionately higher rates of severe and persistent ocular complications than HIV-negative individuals.","abstract":"$32","keywords":["Conjunctiva","Cornea","Eye (Globe)","Infection","Vision"],"pubmed_id":"41469169","conclusions":"","publication_date":"2025-12-31T00:00:00"},"crossref":{"DOI":"10.1136/bjo-2025-328294","URL":"https://doi.org/10.1136/bjo-2025-328294","ISSN":["0007-1161","1468-2079"],"link":[{"URL":"https://syndication.highwire.org/content/doi/10.1136/bjo-2025-328294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"bjo-2025-328294","type":"journal-article","issue":null,"score":1,"title":["Clade-specific ophthalmic manifestations of mpox: an umbrella review and meta-analysis of systematic reviews"],"author":[{"given":"Oscar","family":"Kallay","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Centre Médical de l’Alliance, Braine-l’Alleud, Walloon Brabant (Waals-Brabant), Belgium"}]},{"given":"Luxi","family":"Ji","sequence":"additional","affiliation":[{"name":"Centre Médical de l’Alliance, Brussels, Braine-I’Alleud, Belgium"}]},{"given":"Olalekan A","family":"Uthman","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, Warwick Medical School, Coventry, England, UK"}]},{"given":"Edward J","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, University College London, London, UK"},{"name":"University College London Hospitals NHS Foundation Trust, London, UK"}]},{"given":"Placide","family":"Mbala-Kingebeni","sequence":"additional","affiliation":[{"name":"National Institute of Biomedical Research, Kinshasa, Congo (Democratic Republic of the)"}]},{"given":"Jean-Jacques","family":"Muyembe-Tamfum","sequence":"additional","affiliation":[{"name":"National Institute of Biomedical Research, Kinshasa, Congo (Democratic Republic of the)"}]},{"given":"Elie","family":"Motulsky","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Erasmus Hospital, Brussels, Belgium"}]},{"given":"Jean B","family":"Nachega","sequence":"additional","affiliation":[{"name":"Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"},{"name":"Biomedical Research Institute (BMRI), Stellenbosch University Faculty of Medicine and Health Sciences (FMHS), Cape Town, South Africa"}]}],"funder":[{"id":[{"id":"10.13039/100000061","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000061","name":"Fogarty International Center","award":["5R25TW011217-05"],"award-info":[{"award-number":["5R25TW011217-05"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100010269","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100010269","name":"Wellcome Trust","award":["Grant # 319870/Z/24/Z"],"award-info":[{"award-number":["Grant # 319870/Z/24/Z"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12,30]]},"member":"239","prefix":"10.1136","source":"Crossref","volume":null,"created":{"date-time":"2026-01-01T13:55:46Z","timestamp":1767275746000,"date-parts":[[2026,1,1]]},"indexed":{"date-time":"2026-01-01T13:56:40Z","timestamp":1767275800212,"date-parts":[[2026,1,1]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000,"date-parts":[[2025,12,30]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":"$33","accepted":{"date-parts":[[2025,12,16]]},"language":"en","relation":{},"resource":{"primary":{"URL":"https://bjo.bmj.com/lookup/doi/10.1136/bjo-2025-328294"}},"subtitle":[],"deposited":{"date-time":"2026-01-01T13:55:50Z","timestamp":1767275750000,"date-parts":[[2026,1,1]]},"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"published":{"date-parts":[[2025,12,30]]},"publisher":"BMJ","reference":[{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.1","year":"1972","issue":null,"author":"Ladnyj","volume":"46","first-page":"593","unstructured":null,"article-title":"A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo","journal-title":"Bull World Health Organ","doi-asserted-by":null},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.2","year":"1980","issue":null,"author":"Breman","volume":"58","first-page":"165","unstructured":null,"article-title":"Human monkeypox, 1970-79","journal-title":"Bull World Health Organ","doi-asserted-by":null},{"DOI":"10.1099/vir.0.81215-0","key":"2026010105554218000_bjo-2025-328294v1.3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pntd.0007791","key":"2026010105554218000_bjo-2025-328294v1.4","year":"2019","issue":null,"author":"Beer","volume":"13","first-page":null,"unstructured":null,"article-title":"A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy","journal-title":"PLoS Negl Trop Dis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2207323","key":"2026010105554218000_bjo-2025-328294v1.5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"World Health Organization . Global Mpox dashboard. 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"World Health Organization . Mpox situation reports. 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"World Health Organization . Mpox: multi-country external situation report no. 57. Geneva World Health Organization; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1097/APO.0000000000000608","key":"2026010105554218000_bjo-2025-328294v1.9","year":"2023","issue":null,"author":"Abdelaal","volume":"12","first-page":"326","unstructured":null,"article-title":"Monkeypox-Associated Manifestations and Complications Involving the Eye: A Systematic Review and Meta-Analysis of Previous and Current Outbreaks","journal-title":"Asia Pac J Ophthalmol (Phila)","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41433-022-02195-z","key":"2026010105554218000_bjo-2025-328294v1.10","year":"2023","issue":null,"author":"Abdelaal","volume":"37","first-page":"383","unstructured":null,"article-title":"Ophthalmic manifestations of monkeypox virus","journal-title":"Eye (Lond)","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00705-023-05808-4","key":"2026010105554218000_bjo-2025-328294v1.11","year":"2023","issue":null,"author":"Chenchula","volume":"168","first-page":null,"unstructured":null,"article-title":"A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus","journal-title":"Arch Virol","doi-asserted-by":"crossref"},{"DOI":"10.1097/XEB.0000000000000055","key":"2026010105554218000_bjo-2025-328294v1.12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.n71","key":"2026010105554218000_bjo-2025-328294v1.13","year":"2021","issue":null,"author":"Page","volume":"372","first-page":null,"unstructured":null,"article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.j4008","key":"2026010105554218000_bjo-2025-328294v1.14","year":"2017","issue":null,"author":"Shea","volume":"358","first-page":null,"unstructured":null,"article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1111/hiv.13656","key":"2026010105554218000_bjo-2025-328294v1.15","year":"2024","issue":null,"author":"Brown","volume":"25","first-page":"1086","unstructured":null,"article-title":"Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat","journal-title":"HIV Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(23)00273-8","key":"2026010105554218000_bjo-2025-328294v1.16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11010-022-04657-0","key":"2026010105554218000_bjo-2025-328294v1.17","year":"2023","issue":null,"author":"Thakur","volume":"478","first-page":"2097","unstructured":null,"article-title":"Human monkeypox: epidemiology, transmission, pathogenesis, immunology, diagnosis and therapeutics","journal-title":"Mol Cell Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tips.2023.08.003","key":"2026010105554218000_bjo-2025-328294v1.18","year":"2023","issue":null,"author":"Andrei","volume":"44","first-page":"719","unstructured":null,"article-title":"Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development","journal-title":"Trends Pharmacol Sci","doi-asserted-by":"crossref"},{"DOI":"10.1080/22221751.2025.2456144","key":"2026010105554218000_bjo-2025-328294v1.19","year":"2025","issue":null,"author":"Earl","volume":"14","first-page":null,"unstructured":null,"article-title":"A functional approach to analyze the genetic basis for differences in virulence of monkeypox virus clades","journal-title":"Emerg Microbes Infect","doi-asserted-by":"crossref"},{"DOI":"10.1159/000540815","key":"2026010105554218000_bjo-2025-328294v1.20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/v17091194","key":"2026010105554218000_bjo-2025-328294v1.21","year":"2025","issue":null,"author":"Wang","volume":"17","first-page":"1194","unstructured":null,"article-title":"Evolving Threats: Adaptive Mechanisms of Monkeypox Virus (MPXV) in the 2022 Global Outbreak and Their Implications for Vaccine Strategies","journal-title":"Viruses","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cellin.2024.100185","key":"2026010105554218000_bjo-2025-328294v1.22","year":"2024","issue":null,"author":"Yi","volume":"3","first-page":null,"unstructured":null,"article-title":"The monkeypox virus-host interplays","journal-title":"Cell Insight","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.23","year":"2024","issue":null,"author":"Batool","volume":"16","first-page":null,"unstructured":null,"article-title":"Monkeypox Presenting as Periorbital Cellulitis: A Case Report","journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.1001/jamaophthalmol.2022.5486","key":"2026010105554218000_bjo-2025-328294v1.24","year":"2023","issue":null,"author":"Finamor","volume":"141","first-page":"210","unstructured":null,"article-title":"Tecovirimat Treatment for Monkeypox Virus Keratouveitis","journal-title":"JAMA Ophthalmol","doi-asserted-by":"crossref"},{"DOI":"10.1097/ICO.0000000000003463","key":"2026010105554218000_bjo-2025-328294v1.25","year":"2024","issue":null,"author":"Rosell Domínguez","volume":"43","first-page":"644","unstructured":null,"article-title":"Persistent Monkeypox-Associated Keratouveitis in a Post-LASIK Cornea: A Case Report With Flap Removal","journal-title":"Cornea","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40123-022-00626-4","key":"2026010105554218000_bjo-2025-328294v1.26","year":"2023","issue":null,"author":"Rayati Damavandi","volume":"12","first-page":"55","unstructured":null,"article-title":"A Review of Monkeypox Ocular Manifestations and Complications: Insights for the 2022 Outbreak","journal-title":"Ophthalmol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaophthalmol.2022.4567","key":"2026010105554218000_bjo-2025-328294v1.27","year":"2023","issue":null,"author":"Kaufman","volume":"141","first-page":"78","unstructured":null,"article-title":"Monkeypox Virus and Ophthalmology-A Primer on the 2022 Monkeypox Outbreak and Monkeypox-Related Ophthalmic Disease","journal-title":"JAMA Ophthalmol","doi-asserted-by":"crossref"},{"DOI":"10.2147/IDR.S438725","key":"2026010105554218000_bjo-2025-328294v1.28","year":"2023","issue":null,"author":"He","volume":"16","first-page":"7759","unstructured":null,"article-title":"The Global Health Threat of Monkeypox Virus: Understanding Its Biology, Transmission, and Potential Therapeutic Interventions","journal-title":"Infect Drug Resist","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(19)30294-4","key":"2026010105554218000_bjo-2025-328294v1.29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026010105554218000_bjo-2025-328294v1.30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"World Health Organization . WHO clinical platform dashboard. 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"update-policy":"https://doi.org/10.1136/crossmarkpolicy","alternative-id":["10.1136/bjo-2025-328294"],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"original-title":[],"container-title":["British Journal of Ophthalmology"],"reference-count":30,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,30]]},"references-count":30,"short-container-title":["Br J Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1136/bjo-2025-328294","is_oa":true,"title":"Clade-specific ophthalmic manifestations of mpox: an umbrella review and meta-analysis of systematic reviews","updated":"2026-01-03T00:50:51+00:00","published_date":"2025-12-30","best_oa_location":{"url":"https://bjo.bmj.com/content/bjophthalmol/early/2025/12/30/bjo-2025-328294.full.pdf","pmh_id":null,"url_for_pdf":"https://bjo.bmj.com/content/bjophthalmol/early/2025/12/30/bjo-2025-328294.full.pdf","url_for_landing_page":"https://doi.org/10.1136/bjo-2025-328294"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"condition","value":"Mpox","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"sample_size","value":"n=28139","value_numeric":28139},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"warning","value":"Criteria for “advanced HIV” and exact antiretroviral or immunologic status are not specified in the excerpt.","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"warning","value":"Design is an umbrella review of systematic reviews; classification as a standard systematic review/meta-analysis may not fully capture overlap across primary studies.","value_numeric":null},{"paper_doi":"10.1136/bjo-2025-328294","tag_type":"warning","value":"Risk of bias, heterogeneity, and clade definitions are not detailed in the provided text.","value_numeric":null}],"summaries":{"what_studied":"An umbrella review and meta-analysis of five systematic reviews (36 primary studies; 28,139 laboratory-confirmed mpox cases) assessing ophthalmic manifestations by viral clade (I, II, IIb), with searches from inception to September 2025.","key_result":"Conjunctivitis occurred in 8.9% (95% CI 4.8–13.9) overall, highest with clade I (21.9%) and lowest with clade IIb (2.7%). Keratitis (1.5%), eyelid lesions (3.3%), conjunctival lesions (8.4%), and corneal ulceration (3.3%) varied by clade; visual impairment was 4.5% overall, with unilateral (0.9%) and bilateral (0.4%) blindness reported only in clade I, and advanced HIV was linked to higher rates of severe, persistent ocular complications than in HIV-negative individuals.","practice_takeaway":"Mpox can cause preventable vision loss, especially with clade I and in people with advanced HIV. Early recognition, ready access to eye care, and integration of HIV and mpox services are critical to reduce harm."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Mpox"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Mpox"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Mpox"}}}]]

Papers